Biotech and Drug Discovery
The complete mathematical derivation, formal proofs, and detailed technical specifications are proprietary intellectual property of Opoch. This public document provides a conceptual overview only. For licensing inquiries or research collaboration, contact hello@opoch.com.
Summary
Drug discovery is not an art; it is systematic elimination over a finite intervention space, filtered by a multi-level test hierarchy. The "optimal next experiment" is not intuition; it is the computation that maximizes expected refinement per cost. "Mechanism" is not a story; it is the frontier over causal hypotheses that remains honest under available evidence.
Impact on the World
| Domain | Impact |
|---|---|
| Pharma R&D | Replaces intuition with systematic test selection that maximizes information per dollar |
| Clinical Trials | Honest tracking of what is known vs. unknown at each stage |
| Regulatory | Auditable evidence chains from candidate to approval |
| AI in Drug Discovery | Precise role definition: AI proposes tests, not conclusions |
The Foundation
Intervention Space
Every real drug discovery program has a finite, enumerable set of candidates under consideration — a library, screening set, or synthesis queue.
Multi-Level Test Hierarchy
Drug development proceeds through increasingly costly and informative tests:
| Level | Type | Approximate Cost | Throughput |
|---|---|---|---|
| T1 | In-silico | Low | ~10^6 candidates |
| T2 | In-vitro | Medium | ~10^4 candidates |
| T3 | Cell-based | Higher | ~10^3 candidates |
| T4 | Animal models | High | ~10^2 candidates |
| T5 | Clinical trials | Very high | ~10 candidates |
| T6 | Post-market | Highest | ~1 candidate |
Each level is typically prerequisite for the next.
What Gets Derived (Overview)
From the kernel foundations, the following structures are forced:
1. Candidates and Survivors
The candidate space is finite. A ledger records executed tests and their outcomes. Survivors are candidates consistent with all recorded outcomes. Each test execution shrinks (or maintains) the survivor set — monotone elimination.
2. Target Predicate
Success is defined as a conjunction of verifiable tests. A candidate succeeds if and only if it passes all required tests. The target must be total (defined for all candidates), witnessable (each test produces checkable evidence), and conjunctive (no probability, only witnessed facts).
3. Optimal Test Selection
The optimal next test minimizes worst-case uncertainty per unit cost. Choose the test that, in the worst case over outcomes, maximally shrinks the survivor set per unit cost. This is refinement maximization under cost constraint.
4. AI's Role as Test Proposer
AI systems proposing candidates perform test construction. AI contributions are valuable when they propose tests that have lower cost, higher discrimination, or are outside the human-enumerable test set. The role is precise: AI extends the feasible test set by proposing novel separators.
5. Mechanism as Frontier
A "mechanism" is a causal hypothesis about why a candidate works. The set of plausible mechanisms forms a frontier with statuses: resolved (evidence confirms or refutes), open (insufficient evidence), or undecidable (no feasible test can distinguish). Claiming mechanism without witnessing tests is invalid.
The Discovery Loop
The complete drug discovery process:
- Initialize: Finite candidate library, empty ledger, target predicates
- Compute survivors: Candidates consistent with ledger
- Check termination: Success (candidate passes all tests), failure (all candidates fail some test), or frontier (budget exhausted)
- Select optimal test: Maximize refinement per cost
- Execute test: Record outcome
- Update: Ledger, survivors, mechanism frontier
- Repeat until termination
Why Drug Discovery Fails (Structural Analysis)
| Failure Mode | Structural Cause | Manifestation |
|---|---|---|
| Minted efficacy claims | Claiming success without executing all tests | Failed Phase III after "promising" early data |
| Quotient pollution | Tests too weak to separate candidates | "Me-too" drugs that don't improve |
| Frontier dishonesty | Claiming mechanism without evidence | Papers retracted when mechanism proven false |
| Cost-ignorant selection | Expensive tests before cheaper alternatives | Budget exhaustion before candidate identified |
Verification Requirements
A proof bundle for drug discovery must include:
| Check | What It Verifies |
|---|---|
| Candidate Witness | Candidate is in domain and consistent with ledger |
| Test Definitions | Each test is total with finite outcomes and known cost |
| Raw Data Evidence | Outcomes reproducible from raw data |
| Verifier Execution | All target predicates executed and passed |
| Ledger Receipts | Full audit trail with monotone survivor decrease |
| Frontier Honesty | Mechanism claims match available evidence |
Key Insights
-
Finite domain — Every real program has enumerable candidates.
-
Hierarchical tests — Costs and information increase together.
-
Conjunction target — Success is AND of witnessable tests, not probability.
-
Optimal selection — Maximize refinement per cost, not intuition.
-
AI as separator — AI proposes tests, humans verify.
-
Honest frontiers — Mechanisms are tracked, not claimed.
Drug discovery is systematic elimination:
- Intervention space: Finite domain of candidates
- Test algebra: Multi-level hierarchy with costs
- Target predicate: Conjunction of witnessable tests
- Discovery process: Elimination via optimal test selection
- Mechanism: Frontier over causal hypotheses, honestly tracked
This is the complete derivation: drug discovery is quotient collapse under test algebras with canonical receipts.
No art. No intuition. Only structural collapse with verification.
For the complete derivation: Contact Opoch for licensing and collaboration opportunities.
Email: hello@opoch.com
OPOCH - www.opoch.com